Keythera Pharmaceutical
- Biotech or pharma, therapeutic R&D
Founded in 2018, Keythera Pharmaceuticals is a clinical-stage biotech company developing innovative therapies for cancer and autoimmune diseases. Powered by its proprietary affinity-based high-throughput screening platform, Keythera has built a strong pipeline of novel small molecules. Its lead asset, KF-0210, a selective EP4 antagonist, is in clinical trials for cancer and osteoarthritis. KBP-2205, a selective PARP1 inhibitor, is also in Phase 1 for oncology. KF-2073, a selective MRGPRX2 antagonist, has demonstrated favorable PK and safety, showing best-in-class potential for mast cell–mediated diseases such as CSU and AD.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}